Green Cross to develop high-volume vaccine for elders for first time in Korea
An influenza vaccine which is more effective for elders will be developed.
Green Cross(CEO Eun-Cheol Huh) announced on the 19th that it acquired approval for the Phase I clinical trial plan of a high-volume tetravalent influenza vaccine ‘GC3114’ from the Ministry of Food and Drug Safety.
This i...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
